12:00 AM
 | 
May 25, 2015
 |  BioCentury  |  Emerging Company Profile

Dimension's intentions

Dimension maximizing full capsids for more potent, safer gene therapy

With an industry veteran at the helm and its lead program partnered and paid for, Dimension Therapeutics Inc. aims to develop safer and more potent gene therapies by packaging as many gene copies into capsids as possible.

Dimension debuted in 2013 with a series A round and an option to NAV vector technology from RegenxBio Inc. Dimension has since exercised the option to license exclusive, worldwide rights to a portfolio of liver-targeted AAV vectors for up to eight programs. Dimension's four disclosed programs all use the RegenxBio vectors.

Within a year, Dimension secured Bayer AG's Bayer HealthCare unit as a partner for hemophilia A program DTX201 and hired Annalisa Jenkins as CEO. Jenkins was EVP and head of global R&D at Merck KGaA's Merck Serono S.A. unit. Prior to that she was SVP of global medical at Bristol-Myers Squibb Co.

Dimension's lead internal program, DTX101, is an AAVrh10 vector delivering wild-type Factor IX for hemophilia...

Read the full 808 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >